Clenbuterol

Selective beta-2 adrenergic receptor agonist. Causes smooth muscle relaxation in bronchi — hence bronchodilatory medical use. Also activates beta-2 receptors in skeletal muscle, increasing cAMP and activating protein kinase A — leading to anabolic effects in muscle tissue. Thermogenic — increases body temperature through elevated metabolic rate.

Non-steroid. No ester. Oral or injectable administration. Long half-life of 36-48 hours — once daily dosing sufficient. Accumulates with repeated dosing.

Clenbuterol is used in performance settings primarily as a thermogenic and muscle-sparing agent during cutting phases. The beta-2 adrenergic stimulation increases metabolic rate and promotes fat oxidation while the mild anabolic effect in skeletal muscle helps preserve lean tissue in a caloric deficit. Bodybuilders use it in the final weeks of contest prep when maximum fat loss with muscle preservation is the priority. It is also used by athletes in weight-class sports to manage weight before competition because of its combined fat loss and fluid-related body composition effects.

Clenbuterol appears in contest prep stacks alongside T3 as the classic fat loss combination, where the beta-adrenergic stimulation of Clenbuterol and the metabolic acceleration of T3 produce additive effects on fat oxidation. This combination also creates additive cardiovascular stress and the combined risks are greater than either compound alone. In bodybuilding prep stacks it is often added to an anabolic base of Testosterone and Masteron or Trenbolone in the final weeks. It is sometimes combined with Ketotifen to reduce beta-receptor downregulation and extend the window of effectiveness.

• Asthma bronchodilation — approved in some countries, not in India or USA
• COPD — obstructive airway disease
• Veterinary — equine bronchodilator (Ventipulmin), tocolytic in cattle
• Not approved for human use in India or United States

• Tachycardia — elevated heart rate, can be significant
• Tremors — particularly in hands
• Insomnia — CNS stimulant effects
• Hypokalemia — potassium depletion
• Cardiac hypertrophy — documented with chronic use in animal studies
• Arrhythmias — serious risk at elevated doses
• Headache, nausea, sweating
• Tolerance develops rapidly — requiring dose escalation

The cardiovascular side effects are not mild and they are not entirely reversible with chronic use. Tachycardia during use can be severe enough to be functionally limiting and genuinely uncomfortable. Cardiac hypertrophy with chronic use has been documented in animal studies and is a reasonable concern in humans given the mechanism. The tolerance development that occurs within days of starting use drives dosing escalation to maintain effect, and the side effects escalate with dose. Hypokalemia creates a real arrhythmia risk, particularly when combined with the cardiovascular stress of training. Insomnia and the associated recovery impairment during a compound specifically used to preserve muscle while training intensely is a significant functional cost.

Detection window of 4-6 days via urine testing. WADA has a threshold level (10 ng/mL) due to documented food contamination — particularly in meat from countries where clenbuterol is used in livestock.